Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.
Elizabeth Lee, MD
Advertisement
Elizabeth Lee, MD, is a medical oncologist for the gynecology oncology program at Dana-Farber Cancer Institute in Boston, Massachusetts.
Articles by Elizabeth Lee, MD
Elizabeth Lee, MD, shares that rinatabart sesutecan’s mechanism of action may allow more patients with advanced endometrial cancer to receive effective treatment.
Advertisement
Latest Updated Articles
Why Does Rina-S Target Folate Receptor Alpha in Endometrial Cancer?Published: January 14th 2026 | Updated:
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves TTFields Device With Chemo in Pancreatic Cancer
2
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers
3
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
4
Improving Patient Adherence Through Integrative Oncology Care
5